"I wanted to close the chapter completely … and I feel like that [carrying naloxone] would keep it open a little bit": Refusal to carry naloxone among newly-abstinent opioid users and 12-step identity.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
08 2021
Historique:
received: 02 10 2020
revised: 01 03 2021
accepted: 02 03 2021
pubmed: 26 3 2021
medline: 14 9 2021
entrez: 25 3 2021
Statut: ppublish

Résumé

12-step programs aim to address drug-related harms, like opioid overdose, via abstinence. However, abstaining from opioids can diminish tolerance, which increases risk for overdose death upon resumption. A recent study found that desire to abstain from drugs inhibited willingness to participate in take-home naloxone programming, which was linked to perceptions of harm reduction strategies being tied to drug use. In the present study, we uncovered a similar phenomenon occurring among newly-abstinent participants who were refusing to carry naloxone. This study is an analysis of broader qualitative data collected throughout Southern California among persons who use opioids, including those recently abstinent. Preliminary analysis revealed that those newly abstinent refused to accept naloxone at the end of interviews, and so we began probing about this (N=44). We used thematic analysis and author positionality to explicate the emergent phenomenon and applied social identity theory to conceptualize findings. Mechanisms underlying naloxone refusal included its tie to a drug-using identity that newly-abstinent participants were attempting to retire. Carrying naloxone was also viewed as pointless due to doubt of witnessing an overdose again. Furthermore, the thought of being equipped with naloxone was not believed to be congruent with an abstinent identity, e.g. "me carrying it [naloxone] is making me feel like I'm going to be hanging out with people that are doing it [using drugs]." Recent detoxification heightens vulnerability to overdose, which other newly-abstinent peers might be positioned to respond to as bonds are formed through 12-step identity formation. However, naloxone is often refused by this group due to perceived 12-step identity clash. While some treatment spaces distribute naloxone, 12-step identity associated behavioral expectations appear to conflict with this strategy. Reframing these disconnects is essential for expanding the lifesaving naloxone community safety net.

Sections du résumé

BACKGROUND
12-step programs aim to address drug-related harms, like opioid overdose, via abstinence. However, abstaining from opioids can diminish tolerance, which increases risk for overdose death upon resumption. A recent study found that desire to abstain from drugs inhibited willingness to participate in take-home naloxone programming, which was linked to perceptions of harm reduction strategies being tied to drug use. In the present study, we uncovered a similar phenomenon occurring among newly-abstinent participants who were refusing to carry naloxone.
METHODS
This study is an analysis of broader qualitative data collected throughout Southern California among persons who use opioids, including those recently abstinent. Preliminary analysis revealed that those newly abstinent refused to accept naloxone at the end of interviews, and so we began probing about this (N=44). We used thematic analysis and author positionality to explicate the emergent phenomenon and applied social identity theory to conceptualize findings.
RESULTS
Mechanisms underlying naloxone refusal included its tie to a drug-using identity that newly-abstinent participants were attempting to retire. Carrying naloxone was also viewed as pointless due to doubt of witnessing an overdose again. Furthermore, the thought of being equipped with naloxone was not believed to be congruent with an abstinent identity, e.g. "me carrying it [naloxone] is making me feel like I'm going to be hanging out with people that are doing it [using drugs]."
CONCLUSION
Recent detoxification heightens vulnerability to overdose, which other newly-abstinent peers might be positioned to respond to as bonds are formed through 12-step identity formation. However, naloxone is often refused by this group due to perceived 12-step identity clash. While some treatment spaces distribute naloxone, 12-step identity associated behavioral expectations appear to conflict with this strategy. Reframing these disconnects is essential for expanding the lifesaving naloxone community safety net.

Identifiants

pubmed: 33765517
pii: S0955-3959(21)00098-0
doi: 10.1016/j.drugpo.2021.103200
pmc: PMC10155624
mid: NIHMS1820927
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Naloxone 36B82AMQ7N

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

103200

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA039767
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA040648
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA023356
Pays : United States
Organisme : NCIPC CDC HHS
ID : U01 CE002778
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Addiction. 2008 Oct;103(10):1648-57
pubmed: 18821875
Harm Reduct J. 2017 Dec 06;14(1):77
pubmed: 29212507
Int J Drug Policy. 2014 Jan;25(1):157-65
pubmed: 23932166
Soc Sci Med. 2017 May;180:20-27
pubmed: 28315595
Can J Public Health. 2020 Aug;111(4):606-609
pubmed: 32221867
Soc Sci Med. 2020 Sep;260:113190
pubmed: 32673794
J Urban Health. 2003 Jun;80(2):261-73
pubmed: 12791802
Qual Health Res. 2019 Feb;29(3):345-356
pubmed: 30311841
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
J Urban Health. 2019 Feb;96(1):12-20
pubmed: 30073598
Health (London). 2022 Mar;26(2):139-161
pubmed: 32529843
J Clin Psychol. 2006 Jun;62(6):735-50
pubmed: 16538654
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631-5
pubmed: 26086633
Addiction. 2005 Mar;100(3):397-404
pubmed: 15733253
Int J Drug Policy. 2010 May;21(3):186-93
pubmed: 19268564
J Addict Med. 2014 May-Jun;8(3):153-63
pubmed: 24874759
Drug Alcohol Depend. 2006 Jun 28;83(2):111-21
pubmed: 16338102
Sociol Health Illn. 2019 Feb;41(2):427-443
pubmed: 30710415
J Psychoactive Drugs. 2018 Jul-Aug;50(3):240-246
pubmed: 29424656
Front Psychol. 2015 Nov 30;6:1795
pubmed: 26648882
J Psychoactive Drugs. 2010 Dec;42(4):425-33
pubmed: 21305907
Subst Use Misuse. 2004 Jun;39(7):1117-36
pubmed: 15387206
Int J Drug Policy. 2011 May;22(3):189-93
pubmed: 21055914
JAMA. 2018 May 1;319(17):1819-1821
pubmed: 29715347
Int J Epidemiol. 1993 Apr;22(2):273-7
pubmed: 8505184
J Community Health. 2013 Feb;38(1):133-41
pubmed: 22847602
J Consult Clin Psychol. 2012 Feb;80(1):43-53
pubmed: 22040285
Subst Use Misuse. 2020;55(13):2079-2086
pubmed: 32646279
Addiction. 1999 Jul;94(7):961-72
pubmed: 10707430

Auteurs

J M Bowles (JM)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States; Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.

L R Smith (LR)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.

M L Mittal (ML)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.

R W Harding (RW)

School of Community Health Sciences, University of Nevada, Reno, United States.

E Copulsky (E)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.

G Hennessy (G)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.

A Dunkle (A)

Solace Foundation, CA, United States.

P J Davidson (PJ)

University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States. Electronic address: pdavidson@health.ucsd.edu.

K D Wagner (KD)

School of Community Health Sciences, University of Nevada, Reno, United States. Electronic address: karlawagner@unr.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH